5-Hydroxytryptophan attenuates somatic signs of nicotine withdrawal

J Pharmacol Sci. 2011;117(2):121-4. doi: 10.1254/jphs.11074sc.

Abstract

Abrupt nicotine cessation after chronic use disrupts monoaminergic systems and causes withdrawal signs/symptoms. In this study, the precursor of serotonin 5-hydroxytryptophan (5-HTP) relieved nicotine withdrawal signs. (-)-Nicotine bitartrate or equimolar sodium tartrate was infused into each rat via a s.c. osmotic minipump for 7 days. Somatic abstinence signs (teeth-chattering/chews and shakes, etc.) were counted one day after pump removal. Somatic signs were attenuated by the i.p. injection of 5-HTP, but not by NSD-1015, a centrally-acting L-aromatic amino acid decarboxylase inhibitor, indicating that 5-HTP mitigates somatic signs mainly through its conversion to 5-HT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5-Hydroxytryptophan / therapeutic use*
  • Animals
  • Aromatic Amino Acid Decarboxylase Inhibitors
  • Behavior, Animal / drug effects
  • Hydrazines / pharmacology
  • Male
  • Nicotine / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Serotonin Agents / therapeutic use*
  • Smoking Cessation*
  • Substance Withdrawal Syndrome / drug therapy*

Substances

  • Aromatic Amino Acid Decarboxylase Inhibitors
  • Hydrazines
  • Serotonin Agents
  • Nicotine
  • 3-hydroxybenzylhydrazine
  • 5-Hydroxytryptophan